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Abstract
Background: Epilepsy is a common neurological disorder, which is attributed to uncontrollable abnormal hyper-
excitability of neurons. We investigated the feasibility of using low-intensity, pulsed radiation of focused ultrasound
(FUS) to non-invasively suppress epileptic activity in an animal model (rat), which was induced by the
intraperitonial injection of pentylenetetrazol (PTZ).
Results: After the onset of induced seizures, FUS was transcranially administered to the brain twice for three
minutes each while undergoing electroencephalographic (EEG) monitoring. An air-backed, spherical segment
ultrasound transducer (diameter: 6 cm; radius-of-curvature: 7 cm) operating at a fundamental frequency of 690 KHz
was used to deliver a train of 0.5 msec-long pulses of sonication at a repetitive rate of 100 Hz to the thalamic
areas of the brain. The acoustic intensity (130 mW/cm
2) used in the experiment was sufficiently within the range of
safety guidelines for the clinical ultrasound imaging. The occurrence of epileptic EEG bursts from epilepsy-induced
rats significantly decreased after sonication when it was compared to the pre-sonication epileptic state. The PTZ-
induced control group that did not receive any sonication showed a sustained number of epileptic EEG signal
bursts. The animals that underwent sonication also showed less severe epileptic behavior, as assessed by the
Racine score. Histological analysis confirmed that the sonication did not cause any damage to the brain tissue.
Conclusions: These results revealed that low-intensity, pulsed FUS sonication suppressed the number of epileptic
signal bursts using acute epilepsy model in animal. Due to its non-invasiveness and spatial selectivity, FUS may
offer new perspectives for a possible non-invasive treatment of epilepsy.
Background
Epilepsy manifests developmental, cognitive, socioeco-
nomic, and medical implications while the associated
costs to society are staggering [1]. Anticonvulsant medi-
cations represent the first line of treatment for epilepsy.
Although anti-epileptic/anti-ictal medications are readily
available, approximately one third of patients are resis-
tant to these pharmacological treatments [2]. To allevi-
ate/treat intractable epilepsy with a localized origin,
invasive neurosurgical approaches are adopted, such as
surgical resection of the epileptogenic regions [3]. Sub-
dural and epidural cortical stimulation, vagus nerve sti-
mulation (VNS), and deep brain stimulation (DBS) have
also been considered as viable treatment options [4].
However, these surgical approaches accompany inevita-
ble risks associated with their invasiveness [5]. There-
fore, a new and non-invasive treatment option is
warranted to reduce or even extinguish epileptogenic
activity.
Several non-invasive techniques are being tested for
the suppression of epileptic activity [6]. For instance,
transcranial magnetic stimulation (TMS) was suggested
as a potential tool for the non-invasive treatment of epi-
lepsy [7,8]. However, due to the inductive nature of
magnetic stimulation, the area of modulation affected by
the TMS is rather wide (on the order of several centi-
meters) and is limited to the cortical surface [9]. Tran-
scranial direct current stimulation (tDCS) has also been
introduced to suppress epileptic seizures through direct
injection of electrical current into the brain [10]; never-
theless, it also lacks spatial specificity and suffers from a
limited depth of penetration [6].
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(FUS) techniques allow for the non-invasive and spa-
tially-accurate (on the order of millimeters) transcranial
delivery of acoustic energy (in the form of mechanical
and thermal energy) to a focused tissue region [11]. Sev-
eral investigations of the effects of FUS on the ex vivo
animal brain have revealed that ultrasound can tempora-
rily modify the excitability of the neuronal tissue [12],
which is possibly mediated by the regulation of ion
channels without raising the local tissue temperature
[13]. Ultrasound is also known to decrease cortical
excitability, as it has been demonstrated by concurrent
monitoring of visual evoked potentials in cats [14]. We
recently demonstrated that the administration of low-
intensity FUS (spatial-peak temporal average intensity;
Ispta < 165 mW/cm
2) to a regional brain area, delivered
in a train of pulses, modulated (i.e., excited or sup-
pressed) neuronal excitability in vivo [15,16]. The modu-
lation was achieved without altering the tissue
temperature. By utilizing such a modulatory property of
the pulsed sonication, especially to decrease the excit-
ability, we were motivated to further examine if the FUS
could reduce hyper-excitability of neural tissue based on
a chemical kindling model of acute-stage epilepsy.
The goal of the study was to investigate the feasibility
of using pulsed FUS to suppress epileptic neural activity,
which was induced by the intraperitonial injection of
pentylenetetrazol (PTZ) into rats. PTZ, a gamma-ami-
nobutyric acid (GABA) receptor antagonist (particularly
GABAA-receptor), has been extensively used in animal
models to study acute-stage epilepsy [17]. An acute
stage of epilepsy can be induced by a single dose of
PTZ [18], which increases neuronal excitability across
the entire brain volume with dominant hyper-excitability
across the thalamus [19]. In this respect, we applied
pulsed ultrasound to the brain to sonicate the entire
thalamic area of rats with PTZ-induced acute epilepsy
and measured subsequent electroencephalogram (EEG)
activity to evaluate the degree of epileptic activity.
Although the different thalamic subdivisions may differ
in their roles in epilepsy [20], FUS in the present study
was targeted to sonicate most of the thalamic area glob-
ally rather than its specific subdivisions. Therefore, soni-
cation allows for the examination of the global effects
of FUS on the thalamus and its potential role in the
suppression of epileptic discharges. The results were
compared to EEG activity observed in a group of PTZ-
induced epileptic rats that did not receive sonication.
Behavior of the animals after the treatment was also
monitored, and the results were compared between the
groups. In order to evaluate the safety of sonication
itself, histological analysis was performed on the epi-
lepsy-free animals to assess tissue or vascular damage at
different time points after the sonication.
Methods
Study overview
All procedures were carried out in accordance with the
ethical and safety rules set forth by the Institutional
Animal Care and Use Committee of Harvard Medical
School (protocol # 04608). Male Sprague-Dawley rats
(280 ± 24 g prior to the epilepsy induction; n =2 7 )
were randomly divided into three groups. Those in
Group 1 (induction of acute epilepsy via PTZ injection)
were treated with FUS sonication on the brain after
PTZ-administration (n = 9: noted as ‘PTZ(+)/FUS(+)’).
This group allowed us to investigate the effects of soni-
cation on an acute seizure model. Group 2 (PTZ
injected rats without sonication; n = 9: noted as ‘PTZ
(+)/FUS(-)’) provided a control condition to evaluate the
EEG features of PTZ-induced epilepsy in the absence of
sonication. Group 3 (n = 9) underwent sonication with-
out the epilepsy induction (noted as ‘PTZ(-)/FUS(+)’)t o
provide another condition that was aimed to examine
t h ep r e s e n c eo fp o t e n t i a lt i s s u ed a m a g ei m p o s e db yt h e
ultrasound. Group 3 allowed us to investigate the biolo-
gical effects of FUS alone without the potential con-
founding effects associated with PTZ-induced neural
damage. EEG measurements were not obtained from the
non-epileptic animals in Group 3 since they were used
solely to assess the extent of potential tissue damage
imposed by sonication.
Focused ultrasound sonication setup
An air-backed, spherical segment ultrasound transducer
(diameter: 6 cm; radius-of-curvature: 7 cm) operating at
a fundamental frequency of 690 KHz was used. This fre-
quency is applicable for transcranial applications whereby
the frequency range of 440 to 700 KHz has an optimal
transmission gain through the ex vivo human skull
[21,22]. The transducer was actuated by an electrical sig-
nal generated by a function generator (Agilent, Santa
Clara, CA) which was concurrently amplified using a
power amplifier (403LA, ENII n c ,R o c h e s t e r ,N Y ) .T h e
acoustic power generated for the given electrical signal as
well as its spatial distribution were measured by a cali-
brated needle hydrophone (HNR500, ONDA, Sunnyvale,
CA) mounted on a high-resolution 3-axis robotic stage
(BiSlides, Velmex, Bloomfield, NY). The acoustic focus
was roughly cigar-shaped and measured 3.5 mm in dia-
meter and 6.2 mm in length at the full-width-at-half-
maximum (FWHM) of the acoustic pressure field. We
estimated the pressure amplitude after taking into
account ultrasound attenuation through the rodent skull
in situ (~ 87% of incoming sonication intensity; [23]).
The sonication parameters were controlled by soft-
ware that changes the output pattern of the electrical
signals from the function generator via a direct USB
l i n k( S o n o m o ,S e n s M e d ,N e w t o n ,M A ) .B a s e do no u r
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sonication on the rabbit brain [15,16], the following
sonication parameters were used in the present study:
0.5 ms for the tone burst duration (TBD), 100 Hz for
the pulse repetition frequency (PRF), and 130 mW/cm
2
(Ispta) for acoustic intensity (expressed as power per unit
area). The number of pulse trains determined the dura-
tion of sonication, and Ispta was computed by a pulse
intensity integral (PII) at the pulse repetition frequency.
PII was estimated from the integral of the square of
instantaneous pressure divided by the characteristic
acoustic impedance [24]. This intensity value corre-
sponded to 2.6 W/cm
2 in terms of spatial-peak pulse-
average intensity (Isppa). The maximum peak negative
pressure (
MaxPn in Pascal: Pa) at this parameter value
was measured to be 0.27 MPa, which implies that
damage to the tissue due to the pressure wave is highly
unlikely [13]. Cavitation-related brain tissue damage, in
the absence of air bubbles, is rare at pressures less than
40 MPa [25]. The mechanical index (MI), which is
defined as the
MaxPn of a longitudinal ultrasound wave
propagating in a uniform medium divided by the square
root of its center frequency, is used as the first-order
limit to describe the safety of ultrasound devices. The
MI of the present study (0.33) is also sufficiently low
relative to the regulatory-limit for ultrasound procedures
(i.e., 1.9 for all applications except ophthalmic (maxi-
m u m0 . 2 3 ) ;[ 2 6 ] ) .A d d i t i o nally, our MI of 0.33 is less
than the threshold for the blood-brain barrier (BBB) dis-
ruption in the presence of injected microbubbles (e.g.,
MI of 0.47; [27]). Without microbubbles to amplify the
effects of acoustic pressure, the BBB is hardly disrupted,
even at much higher acoustic intensities [27].
The FUS sonication apparatus is displayed in Figure 1A.
The transducer was mounted on the 3-axis positioning
system (UniSlides, Velmex, Bloomfield, NY) and was sub-
merged in degassed water. The animal was laid supine on
a plastic tray mounted above the system, and the head was
partially submerged into an oval hole that opened into a
bag of degassed water to secure an uninterrupted path
from the transducer to the targeted tissue. To provide the
same experimental stress conditions across all groups, the
animals in Groups 2 and 3 underwent the same physical
restraint method as did the epileptic animals in Group 1.
The animal’s head and body were gently restrained using
tapes to prevent potential movement-related EEG artifacts.
Prior to the animal experiment, the coordinates of the
acoustic focus were positioned at the center of an oval
hole under the metric guidance of the stereotactic coordi-
nates of rats [28]. Since PTZ typically induces neuronal
excitation across the whole brain volume with dominant
hyper-excitability in the thalamic areas [19,29,30], the
sonication focus was targeted to the thalamus (about 5
mm deep from the surface, along the midline, and 2 mm
posterior to the bregma; cf. Figure 1B). Specifically, the
sonication focus and the beam path were large enough to
affect most of the thalamic areas.
Animal preparation and pre-epilepsy EEG setup
Food and water were provided ad libitum to animals that
were in a controlled day/night condition (12 hr/12 hr).
All animals were anesthetized with an intraperitonial
Figure 1 A diagram of the experimental apparatus and the topographical arrangement of the sonication path and electrodes. (A) The
transducer was mounted on a 3-axis stereotactic positioning system and submerged in degassed water. The coordinates of the acoustic focus
were controlled under the metric guidance of the stereotactic coordinates of the rat brain, which were marked on a plastic plate. After
localization of the acoustic focus, the animal was laid supine on a plastic tray that was mounted above the system. The head was partially
submerged in an oval hole that opened into a bag of degassed water in order to secure an uninterrupted beam profile from the transducer to
the targeted tissue. (B) Schematic diagram of the positions of bilateral subdermal EEG electrodes (marked as small blue circles) relative to the
area of the sonication beam path (marked as a red circular boundary) on the rat skull as well as to the sonication focus (marked as a solid red
circle).
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kg). A pair of thin (~200 μm in diameter) Ag/AgCl elec-
trodes (SWE Ives EEG Solution, Canada) was subder-
mally introduced into both left and right brain regions;
the topographical position of these two electrodes was 6
mm lateral to the midline and 1 mm posterior to the
bregma under the stereotactic guidance (small animal
stereotaxic frame: SAS-4100, ASI instruments, Warren,
MI; cf. Figure 1B; [28]). Since direct sonication of the
electrode itself can potentially introduce significant con-
founding signals to the measured EEG and may also
cause a rise in local tissue temperature due to the absorp-
tion of ultrasound energy (which is highly unlikely due to
the use of a low acoustic energy of 130 mW/cm
2 Ispta),
the electrodes were positioned away from the incident
sonication path as well as the sonication focus (cf. Figure
1B). Given the depth of the sonication focus (5 mm from
the surface) and the relatively flat skull surface (perpendi-
cular to the incident sonication beam), the radius of the
sonication beam on the skull was calculated to be 2.4
mm by a trigonometric relationship of the transducer
geometry (i.e., R = depth at the focus × tan(arcsin(half of
outer diameter of the segmented transducer/radius-of-
curvature)). The electrodes, placed subdermally, were
positioned away from the sonication focus that was inside
the brain. Another electrode was positioned at the tip of
the ear as a ground electrode. The EEG signal was ampli-
fied (PowerLab 8/30, AD Instrument, CO) and recorded
(LabChart 7, AD Instrument, CO) at a sampling rate of
1000 Hz. The EEG signal was recorded for ten minutes
to establish the baseline condition (noted as ‘Block-A’ in
Figure 2 and ‘Baseline’ in Figures 2 and 4).
Induction of epilepsy and FUS sonication
45 mg/kg (based on animal weight) of PTZ prepared in
0.4 mL of normal saline was administered to the animals
in Groups 1 and 2 via intraperitonial injection. EEG was
subsequently acquired for ten minutes (noted as ‘Block-
B’ or ‘Pre-FUS’ in Figure 2) after there was significant
evidence of the epileptic behaviors (e.g., bilateral fore-
paw-twitches). The first dose of FUS sonication was
then delivered to the animals for three minutes (noted
as ‘Block-C’ or ‘FUS1’ in Figure 2). The EEG signals
were measured after the first sonication for additional
ten minutes (noted as ‘Block-D’ or ‘Post1’ in Figure 2).
The second dose of FUS sonication was then adminis-
tered to the animals (noted as ‘Block-E’ or ‘FUS2’ in
Figure 2) for additional three minutes, followed by EEG-
monitoring for another ten minutes (noted as ‘Block-F’
or ‘Post2’ in Figure 2). Upon the completion of the pro-
cedure, the animal was returned back to the cage for
behavioral monitoring that was resumed on the follow-
ing day.
Behavioral monitoring
Behavioral monitoring was performed to evaluate the
effects of sonication on epileptic behavior. The posture
of the animal was evaluated for two weeks using the
established Racine scoring system [31], and evaluation
was performed at the same time on each day (i.e.,
between 10 am-11 am on Days 0-3, 5, 7, 10 and 14).
During this period, the body weight was also monitored
for excessive weight loss (i.e., more than 10% of original
body weight).
Histological analysis
The biological effect of sonication was examined from a
separate group of rats (Group 3: n =9 )w h i c hd i dn o t
undergo PTZ injection. The same experimental proce-
dures were conducted to Group 3 as the other groups
with the exception of PTZ injection. The acute effect of
FUS sonication was examined from three animals that
were sacrificed immediately after the procedure. The
remaining six animals in Group 3 were allowed to sur-
vive after the FUS for either one week (n =3 )o rt h r e e
weeks (n = 3) to monitor any adverse behavioral
changes associated with the procedure. The extracted
brain was fixed with systemic circulation of formalde-
hyde (4% formaldehyde in phosphate buffered saline).
For the preparation of the histological samples, the tis-
sue was cut in the plane perpendicular to the sonication
path. Haematoxylin and eosin (H&E) staining was used
Figure 2 Flowchart of the EEG acquisition and FUS sonication. Block-A represents the baseline period. The baseline EEG was recorded for
ten minutes after the EEG signals stabilized following the administration of anesthesia. Block-B (named as ‘Pre-FUS’) indicates the time-interval
after observing significant evidence of ictal behavior (e.g., bilateral forepaw-twitches) and just before the first sonication. Block-C represents the
three-minute period of the first sonication (named as ‘FUS1’), and Block-E represents the second three-minute sonication interval (named as
‘FUS2’). Block-D represents the time-interval after the first sonication (named as ‘Post1’), and Block-F represents the time-interval after the second
sonication (named as ‘Post2’).
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damages. The presence of DNA fragmental damage was
probed by the terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick end labeling (TUNEL) assay
using the in situ cell death detection kit (Roche, India-
napolis, IN) developed using Cy2-conjugated streptavi-
din (1:500; Jackson Lavoratoried, West Grove, PA). The
nucleus was counterstained with diamidino-2-phenylin-
dole (DAPI). The slides were then examined under a
light/fluorescence microscope (ELIPSE 80i, Nikon,
Tokyo, Japan).
EEG data analysis
We assessed both raw EEG and its theta-band activity.
To analyze EEG data in the frequency domain, band-
pass digital filtering was applied. The band-pass filter
was implemented as a linear phase Finite Impulse
Response (FIR) filter and was designed using the win-
dow method with a Kaiser window [32], giving pass and
stop band ripples of less than 0.5%. The transition width
of filtering was set to 20% of the cut-off frequency. The
cut-off frequency was the frequency where the output
amplitude falls to half the input amplitude (-6 dB). The
cut-off frequency ranging from 4 to 8 Hz (i.e., theta-
bands) was selected for spectral analysis since progres-
sive increments of theta activity has been reported dur-
ing PTZ-induced epilepsy [33,34]. It has also been
suggested that theta-like slow waves are associated with
epileptiform discharges [35]. Although the subdermal
electrode was not generally susceptible to the facial or
paw twitches associated with epileptic activity, the spur-
ious signal fluctuations exceeding 200 μV were excluded
from further analysis.
A qualitative assessment was confirmed by a detailed
quantitative analysis of the observed epileptic spikes. An
automated algorithm was used to detect and count the
number of peaks in the raw EEG signal after thresholding
the signal amplitude within each time block (A to F as
d e s c r i b e da b o v ea n ds h o w ni nF i g u r e2 ) .T h et h r e s h o l d
was set to a value greater than 4.75 standard deviations
from the individual baseline EEG activity (corresponds to
the detection of deviant signal peaks with one-tailed
probability < 10
-6; assuming normal probability distribu-
tion in EEG noise pattern during the baseline state). This
provided the ability to discriminate PTZ-induced epilep-
tic bursts of EEG activity from standard baseline signal
fluctuations. The number of detected peaks was counted
in every one-minute segment and averaged across the
monitoring period. Regarding the analysis of the theta-
band EEG activity, the number of peaks exceeding the
threshold was counted using the same algorithm as in
the raw EEG analysis.
For statistical analyses, an independent two-sample
t-test (one-tailed) was performed on the number of
threshold-exceeding EEG peaks comparing the Group 1
and Group 2. The t-test was also employed for compar-
ing Racine scores between the two groups. The number
of threshold-exceeding EEG signal bursts was also com-
pared within each animal. In this case, a paired t-test
(one-tailed) was applied. In order to compare body
weights of the animals between groups after the sonica-
tion periods, a repeated-measures ANOVA was per-
formed while covarying for the individual body weight
measured before the experiment.
Results
EEG data
Exemplary EEG data acquired from one animal within
each group (Groups 1 and 2) are shown in Figure 3,
whereby both unfiltered EEG recordings and theta-band
activity are displayed. Prior to the PTZ injection, there was
no apparent detection of epileptic EEG signal bursts (see
‘Baseline’ in Figure 4). Within approximately ten minutes
after the administration of PTZ, epileptic signal bursts
were observed in their EEG recordings (see red boxes in
Figure 3 and ‘Pre-FUS’ in Figure 4). As demonstrated in
Figure 3A (see the upper blue box compared to the upper
red box), the number of EEG bursts in the FUS-treated rat
appeared to be reduced after the first sonication (noted as
‘FUS1’), but remained steady in the epileptic rat that did
not receive the sonication (cf. Figure 3B and Figure 4A).
After the second sonication (noted as ‘FUS2’), the number
of bursts was further reduced compared to the number
obtained during and after the first sonication (see the
upper green box compared to the previous red and blue
ones in Figure 3A), whereas the control epileptic rat still
showed a greater number of bursts throughout the entire
monitoring period (cf. Figure 3B and Figure 4A). The EEG
s i g n a l si nt h et h e t a - b a n d ss h o w e ds i m i l a rt r e n d sa st h e
unfiltered signals (cf. Figure 4B).
Between-group effect
Prior to the injection of PTZ, the EEG recordings did
not show any significant differences between the two
PTZ groups (t(16) = 0.430, n.s.). After the PTZ-injec-
tion, both groups manifested a dramatic increase in the
number of epileptic signal bursts, without any significant
group differences (t(16) = -0.321, n.s.). Immediately after
the first sonication (i.e., ‘Post 1’), however, the number
of epileptic EEG bursts decreased in the sonicated group
(t(16) = -1.74, p < 0.05). As shown in Figure 4A, this
suppressive effect (note the significant differences indi-
cated by green brackets in Figure 4A) was maintained
during and after the second sonication (’FUS2’: t(16) =
-2.03, p < 0.05; ‘Post2’: t(16) = -1.72, p < 0.05).
As for the analysis of EEG theta activity, there were
no significant differences between the two groups prior
to the first sonication (’Baseline’: t(16) = -0.754, n.s.;
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induced epileptic rats (A) with sonication and (B) without sonication. In each EEG dataset, the upper signals represent unfiltered (raw) EEG data,
and the lower signals show their corresponding theta-band activity. The insets of magnified windows represent EEG samples for 30 seconds in
each highlighted time-window. Red boxes indicate an interval before the first sonication period, blue boxes indicate an interval between the first
and the second sonication periods, and green boxes indicate an interval after the second sonication period. Note the changes in raw EEG spikes
before, during, and after the sonication in the FUS-treated rat (see the upper red, blue and green boxes in (A)). The ictal activity during the pre-
sonication period started to diminish along with each of the two sonication sessions (marked with gray boxes; FUS1-2) and was effectively
suppressed after the second sonication (see the upper green box in (A)). Vertical scale bars indicate 100 μV in raw EEG signals and 20 μVi n
theta activity. Horizontal scale bars indicate a one-minute time scale (ten seconds for the insets).
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nificant reductions in the number of EEG theta bursts
in the sonicated group after the second sonication
(’Post2’: t(16) = -1.98, p < 0.05; see the green bracket in
Figure 4B). Compared to the second sonication, the first
sonication did not have any significant impact on redu-
cing the number of EEG bursts in the theta-bands
(’Post1’: t(16) = -0.790, n.s.).
Within-group effect
As shown in Figure 4A (see red brackets), the number
of epileptic EEG bursts within the FUS-treated group
was significantly reduced after the first sonication period
(’Post1’: t(8) = 2.26, p < 0.05) compared to the pre-soni-
cation period (’Pre-FUS’) .T h ed e g r e eo fr e d u c t i o nw a s
even greater during and after the second sonication per-
iod (up to 74.5%; ‘FUS2’: t(8) = 1.91, p < 0.05; ‘Post2’:t
(8) = 2.58, p < 0.05). In the FUS-treated group, the
number of epileptic signal bursts in the raw EEG data
was further reduced after the second sonication com-
pared to the number observed during and after the first
sonication (’FUS1’ vs. ‘Post2’: t(8) = 2.73, p <0 . 0 5 ;
‘Post1’ vs. ‘Post2’: t(8) = 2.55, p < 0.05). Compared to
the pre-sonication period, the number of threshold-
exceeding EEG theta peaks was significantly reduced
during (63.0% reduction) and after (up to 68.5% reduc-
tion) the second sonication (’FUS2’: t(8) = 2.81, p <
0.05; ‘Post2’: t(8) = 3.14, p < 0.01). In contrast, the num-
ber of detected signal bursts within the unsonicated epi-
leptic group for both raw and theta EEG activity
remained constant during the entire monitoring period
(compared to the period of full-fledged epileptic EEG
bursts, which corresponds to ‘Pre-FUS’;a l ln.s.). We
observed that the occurrence of threshold-exceeding
raw EEG bursts after the two sonication periods did not
completely recover to the pre-PTZ injection state (i.e.,
the baseline period; t(8) = -2.83, p <0 . 0 5 ) ,w h e r e a st h e
number of threshold-exceeding EEG theta bursts
returned back to the state prior to epilepsy induction (t
(8) = -1.55, n.s.).
Behavioral and histological data
T h eR a c i n es c o r e st h a tw e r em e a s u r e do nt h ed a ya f t e r
the experiment were significantly lower in the FUS-trea-
ted group than those of the unsonicated epileptic group
(t(15) = -2.41, p < 0.05; Group 1: 0.33 ± 0.18, Group 2:
1.13 ± 0.30). This distinction disappeared while the
Racine scores indicated the non-epileptic state after Day
2 (t(15) = -1.75, n.s. ;G r o u p1 :0±0 ,G r o u p2 :0 . 1 3±
0.13). It suggests that both groups recovered from the
acute epilepsy induction by PTZ. The body weight of
the animal, which is an indicator of the long-term sever-
ity of epilepsy, was shown to be indifferent between the
sonicated and unsonicated group (F(1,14) = 0.617, n.s.).
Histological analysis performed on Group 3, indicated
that no detectable tissue damage was observed after the
FUS sonication. Based on TUNEL staining, there was no
apparent indication of DNA fragmentation in the brain
tissue located at or near the sonicated sites (cf. Figure 5)
throughout the monitoring period (up to three weeks).
To further examine the presence of apoptosis, the direct
assessment of caspases (or cysteine-aspartic proteases)
activity is needed [36]. Visual and histological (H&E)
inspection did not show any observable brain tissue
damage in close proximity to the electrodes, which were
located subdermally above the skull.
Figure 4 Analysis of epileptic EEG signal bursts. (A) Comparison of
the average number of threshold-exceeding raw EEG peaks (greater
than 4.75 standard deviations from the individual baseline activity of the
raw EEG data) between the FUS-treated and untreated groups. (B)
Comparison of the average number of EEG theta peaks exceeding the
absolute magnitude above the threshold (4.75 standard deviations from
the individual baseline theta activity) between the same two groups. Red
bars indicate Group 1 (the FUS-treated PTZ group: PTZ(+)/FUS(+)), and
blue bars indicate Group 2 (the untreated epileptic group: PTZ(+)/FUS(-)).
As shown in both graphs, there were no significant differences between
the two groups before the sonication. Red brackets indicate statistically
significant differences (p < 0.05) within the FUS-treated group, and green
brackets indicate statistically significant differences between the two
groups. Error bars indicate standard errors of the mean.
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Our results reveal that low-intensity, pulsed FUS sonica-
tion suppressed the number of epileptic signal bursts
observed in EEG recordings after the induction of acute
epilepsy via intraperitoneal injection of PTZ. The pre-
sence of the suppressive effect was found in terms of
the number of epileptic EEG spikes from the analysis of
the unfiltered (Figure 4A) and theta-band (Figure 4B)
EEG activity. FUS-mediated reduction of epileptic EEG
activity was most notably observed in the theta band.
EEG theta activity has also been consistently reported to
have a positive correlation with the level of epilepsy
[33-35]. Thus, our findings may offer more information
with regard to the possible mechanisms involved in the
reduction of epileptic activity (for example, the region-
specific efficacy of FUS and its manifestation in theta
band activity). The assessment of EEG patterns asso-
ciated with sonication, in the absence of induced epi-
lepsy, will offer rich information on the excitatory or
inhibitory influence of FUS on neural circuitry, and it
will provide more information on the applicability of
FUS to non-pathological conditions. We also found that
the second sonication session further enhanced the sup-
pressive effect beyond that of the first sonication ses-
sion. Based on the analysis of the Racine scores, it
consistently appears that the FUS-treated group recov-
ered from an epileptic state more quickly than the unso-
nicated group.
Taken together, these findings suggest that transcra-
nial FUS sonication provided a significant suppressive
effect on PTZ-induced epileptic activity in rats. These
observations are in good agreement with previous stu-
dies on the temporary suppression of spontaneous activ-
ity in the excised crayfish ventral nerve cord [37] and
on the suppression of visual activity in cats mediated
through insonication of non-focused ultrasound [14].
Although the inferior colliculus of rats is responsive to
ultrasound [38] and can even induce audiogenic seizures
[39,40], our observations are unlikely to be associated
with the auditory responsiveness of the inferior collicu-
lus of rats to ultrasound frequencies. This is because the
ultrasound frequency of the present study (e.g., 690
KHz) was far greater than the audible range (applicable
to rodents, approximately 30 to 70 KHz) of ultrasound
frequencies in which the maximal responsiveness of the
inferior colliculus of rats was observed [38]. Generally,
the rodent species used in this study can process ultra-
sound up to approximately 80 KHz [41-43].
S i n c ee p i l e p t i ca c t i v i t yi sc a u s e db ya b n o r m a l l ye x c e s -
sive or synchronous neural activity in the brain [44], and
synaptic contacts could potentially be disrupted by ultra-
sound waves [45], FUS sonication might reduce the pro-
pagation of epileptic discharges across the brain.
Alternatively, a different hypothesis can be put forth to
explain our findings: FUS sonication may have caused a
reduction in epileptic EEG activity by regulating thalamic
GABAergic inhibitory neurons implicated in epilepsy
[46]. Evaluation of the extracellular neurotransmitter
levels (such as GABA) may offer useful information to
clarify some of these hypotheses through the use of
microdialysis techniques that assay various types of neu-
rotransmitters directly from the brain [47].
Although little is known ab o u tt h ed e t a i l e dm e c h a n -
ism underlying FUS-mediated neuro-modulation, it has
long been reported that ultrasound can significantly
affect the neurophysiology of in vitro local neural circui-
try [48,49]. Gavrilov et al. [12] reported that the main
effect of FUS in stimulating neural structures is due to
mechanical force that could produce alterations in
membrane potential, thus resulting in the stimulation of
neural structures. It has also been proposed that ultra-
sound sonication may influence membrane fluidity, tur-
bidity and permeability [50,51]. Accordingly, the activity
of ion-channels or receptors on the membrane can be
Figure 5 Examples of histology from the sonicated brain area.
Exemplary histological data obtained from Group 3 (PTZ(-)/FUS(+)).
(Left column) H&E staining results and (Right column) TUNEL
staining results (DAPI in blue, apoptotic cell in green) from (A) a
sonicated thalamic site, (B) the cortex above the sonicated thalamus
in the FUS beam path, and (C) an unsonicated posterior cortex.
Note the absence of apoptotic DNA-damaged cells in all of the
examined locations.
Min et al. BMC Neuroscience 2011, 12:23
http://www.biomedcentral.com/1471-2202/12/23
Page 8 of 12influenced by ultrasound sonication [49], and the trans-
membrane concentrations or passage of ions or neuro-
transmitters can be subsequently altered. FUS-mediated
structural alterations in soma/axonal/dendritic connec-
tions may also have attributed to our findings and thus
requires further investigation.
It has been consistently reported that ultrasound soni-
cation activates voltage-gated Na
+ and Ca
2+ channels
[13] and that a FUS-mediated mechanical force can acti-
vate several mechano-sensitive ion channels, allowing
cation entry [52-55] and resulting in alterations in mem-
brane potential [12]. Therefore, FUS-mediated dysfunc-
tion of functional molecules, such as cell membrane
transporters that are sensitive to trans-membrane ion-
concentrations, may lead to biochemically altered states
in the sonicated area. For example, activation of the ser-
otonin transporter (SERT) is modulated by the trans-
membrane gradient of Na
+ and K
+ [56], and trans-mem-
brane ion concentrations are potentially altered by FUS
sonication. Consequently, abnormal SERT activity, pos-
s i b l yb yF U Ss o n i c a t i o n ,m a ya c t u a t eac h a n g ei nt h e
extracellular level of serotonin (5-HT).
In terms of biological safety, it is noteworthy that ultra-
sound sonication can potentially generate free radicals
[57,58]. For example, ultrasound sonication can decom-
pose water into hydrogen and hydroxyl radicals [59].
These free radicals, although short-lived, are extremely
unstable and can react easily with other surrounding bio-
logical molecules, possibly resulting in tissue damage and
inflammatory response [60]. However, these free radicals
are typically produced at high acoustic intensities that are
associated with cavitation [61]. Since the current study
uses an acoustic intensity much lower than those that pro-
duce cavitation and free radicals, sonication in the present
study is unlikely to adversely affect the brain tissue.
As shown in the histological results (cf. Figure 5), the
sonication employed in the present study did not cause
any inadvertent biological damage to the target region.
The intensity of sonication used in the present study
was 130 mW/cm
2 (Ispta), which is far less than the
upper regulatory limit for non-obstetric ultrasound ima-
ging (720 mW/cm
2; [62]). It has been reported that
when a short duration of sonication (5 sec) is used,
ultrasound intensity up to 430 W/cm
2 (at 936 KHz) can
be applied without inducing mechanical damages to the
brain tissue [63]. The MI of the present study was 0.33,
which is sufficiently within the range of safety guidelines
(i.e., 1.9; [26]). Collectively, our sonication parameters
are all within the range of safety guidelines for clinical
ultrasound imaging and demonstrate a significant reduc-
tion of epileptic activity characterized in EEG and beha-
vioral monitoring.
T h ep r e s e n ts t u d yh a ss e v e r a l technical limitations to
overcome. First of all, since the intraperitoneal injection
of PTZ elicits hyper-excitability over the distributed
regions of the brain, region-specific anti-epileptogenic
effects of FUS were not demonstrated. In order to
examine the utility of FUS in suppressing region-specific
epileptogenic activity, a regional chemical kindling
model such as an intracortical injection of kainic acid
(KA) can be adopted to induce focal epileptic lesions in
an animal model. KA induces nonconvulsive status epi-
lepticus, followed by the chronic occurrence of sponta-
neous recurrent seizures and massive hippocampal
damage [64-66]. The regional application of FUS to a
KA-kindled epileptogenic focus for probing its potential
utility in the treatment of chronic focal epilepsy consti-
tutes one of our future subjects of investigation.
Another technical limitation of the study is the spatial
error introduced while positioning the sonication focus.
There are several sources that can contribute to poten-
tial spatial error while targeting the sonication focus to
t h et h a l a m i ca r e a .T h e s es o u r c e si n c l u d et h ei n h e r e n t
mechanical repositioning error of the mechanical 3-axis
stage that mounted the transducer as well as spatial
error associated with acoustic field distortion during
transcranial FUS application. Since these sources typi-
cally introduce errors that are significantly smaller than
the acoustic focus, the major source of spatial error dur-
ing positioning of the focus can be traced to the use of
an external anatomical landmark, i.e., the ear canal and
associated inter-aural lines, during stereotactic position-
ing of the animal with respect to the sonication appara-
tus. Based on the work by Rubins et al. [67], the
potential spatial error associated with the procedure can
be estimated to be on the order of 0.5 mm, which is
approximately 15% of the short-axis diameter of the
FUS focus (3.5 mm in diameter). The characterization
of the exact location and size of the sonication focus in
the brain would clearly improve the spatial accuracy of
sonication delivery. The use of magnetic resonance ima-
ging (MRI) enables an elaborate spatial guidance system
for the application of focused acoustic energy to a
defined anatomical location [11,68,69]. For example, an
MRI-compatible stereotactic positioning system [70,71]
would allow users to track the coordinates of the sonica-
tion focus. Localization of the sonication focus can also
be accomplished by the guidance of acoustic radiation
force impulse (ARFI) imaging which can visualize the
degree of acoustic force imposed on tissues without the
generation of heat [72-74].
It is also noteworthy that FUS can elicit neuronal sti-
mulation with different sets of FUS-parameters (i.e.,
TBD = 50 msec, PRF = 10 Hz in rabbits or TBD = 0.4
msec, PRF = 1500 Hz in rats, and both achieved at a
higher acoustic intensity of Ispta 4~6 W/cm
2;u n p u b -
lished data). Therefore, it is reasonable to predict that
FUS could further exacerbate neuronal hyperactivity in
Min et al. BMC Neuroscience 2011, 12:23
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dependent efficacy of the method and careful selection
of the sonication parameters are needed to develop
appropriate treatment guidelines.
FUS-mediated region-specific functional neuro-modu-
lation promises new, powerful ways to study brain func-
tion and brain-behavior relations. As a result, we
anticipate that this technique may influence the develop-
ment of new modalities for neurotherapeutic treatments
across a wide clinical range. For instance, neurological
conditions that are associated with subcortical structures
(i.e., pain and movement disorders related to abnormal-
ities in the thalamus and elements of the limbic system)
may potentially benefit from FUS due to its ability to
reach deep brain regions in a non-invasive way. Simi-
larly, the modulatory effects of FUS can be utilized to
modify aberrant brain activity and neurotransmission
associated with various psychiatric conditions, such as
depression or post-traumatic stress disorder.
Conclusions
In summary, our findings provide compelling evidence
that FUS sonication holds promise as an elegant non-
invasive therapeutic tool to suppress epileptic activity.
Since FUS-mediated transcranial thermal ablation of
human brain tumors [75] and functional neurosurgical
applications using targeted lesions in the thalamus [76]
have already been accomplished using a commercially-
available transcranial FUS prototype, the translation of
the technique to human application would not encoun-
ter significant technical barriers. Further refinement of
the sonication parameters and subsequent exploration of
selective functional neuro-modulation will be needed to
disseminate the technique across a wide range of
research and clinical fields.
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